MediPharm Labs Corp. (TSX-V: LABS) (OTCQX: MEDIF) (FSE: MLZ) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to provide an update to investors on the significant strategic progress it is making, including with its successful ramp up of production capacity to supply its growing customer base. Founded in […]

MediPharm Labs Corp. (TSX-V: LABS) (OTCQX: MEDIF) (FSE: MLZ) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that its wholly owned subsidiary, MediPharm Labs Inc., has entered into purchase agreements to secure a substantial 9,000 KG of dried cannabis supply from multiple cultivators in the last […]

MediPharm Labs Corp. (OTCQX: MEDIF) (TSX-V: LABS) (FSE: MLZ) announced that the Company has qualified to trade on the OTCQX® Best Market. MediPharm Labs upgraded to OTCQX from the OTCQB® Venture Market and begins trading under the symbol “MEDIF”. MediPharm Labs Corp. announced the appointment of Dr. Paul Tam, MBBS, FRCP(C), FACP to its Board […]

MediPharm Labs Corp. (OTCQB: MLCPF) (TSX-V: LABS) is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc., has entered into its first definitive international sales agreement, dated February 20, 2019, with AusCann Group Holdings Ltd. to supply private label purified, pharmaceutical grade cannabis oil concentrates, or resin, from MediPharm Labs’ own inventory of oil […]

“Buzz on the Street” Show: Featuring MediPharm Labs Cannabis News Recap MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MLCPF) has entered into a significant sales agreement with a leading Licensed Producer to supply approximately $35 million of private label purified cannabis oil concentrates. Under the terms of the agreement, the Licensed Producer will immediately purchase upfront […]